12,372 trials
Hepatitis C, Chronic
Primary: The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12) — 95.9 Percentage of participants
Severe Hemophilia A
Primary: Long-term Immunogenicity — 0 occurrence of inhibitors
Post-Operative Pain
Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48). — 105.60; 55.58 Units on a scale — p=0.001
Human Influenza
Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVc — 66; 41; 98; 84…
Post Operative Pain
Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID48). — 76.24; -11.35 Units on a scale — p=<0.001
Retinitis Pigmentosa
Primary: Central Visual Field (vf) Change Assessed Using the 30-2 Program of the Humphrey Field Analyzer (HFA). — -51.5; -49.6 annual change in db vf sensitivity — p=0.66
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 — 71; 64 Percentage of participants — p=0.030
Cirrhosis
Primary: Body ｗeight — -1.95; -0.44 Kg — p=<0.0001
Cirrhosis
Primary: Body Weight — -1.14; -1.37 kg
Smoking Cessation
Primary: The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds — -14.15; -9.26 mm — p=0.0141
Cardiac Edema
Primary: Body Weight — -2.05; -1.31; -2.9 Kg
Acute Gouty Arthritis
Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
Ototoxicity · Unspecified Adult Solid Tumor
Primary: Ototoxicity Measurement — 7; 7 participants — p=0.89
Human · Influenza
Primary: Percentage of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains After One Vaccination of TIVf — 83; 60; 70; 48…